Global Oligonucleotide Pool Library Market Research Report 2024-Competitive Analysis, Status and Outlook by Type, Downstream Industry, and Geography, Forecast to 2030
Column-based oligo synthesis is the first-generation technology based on phosphoramidite chemistry. Column-based oligonucleotide synthesis cannot satisfy the requirements of large-scale DNA synthesis in the era of synthetic biology, due to the limitations of low throughput and high cost. In the 1990s, oligo synthesis gradually developed into a higher throughput manner by parallel synthesis on a silica surface. This microchip-based (also called ‘microarray-based’) large-scale oligo synthesis technology, surpassing the column-based synthesis in terms of throughput and cost, has received wide attention.
A promising route is to harness existing DNA microchips, which can produce up to a million different oligonucleotides on a single chip, as a source of DNA. Recently, the quality of microchip-synthesized oligonucleotides was improved by controlling depurination during the synthesis process. These arrays produce up to 55,000 200-mer oligonucleotides on a single chip and are sold as a ~1–10 picomole pools of oligonucleotides, termed OLS pools (oligo library synthesis). The currently cheapest available source of synthetic DNA is micro‐array‐synthesized oligonucleotides, commercially available as oligo pools. Oligo pools are mixes of thousands of individually designed polynucleotides of up to 350 bases in length. Microarray‐based technologies allow the synthesizing of thousands of individual user‐defined sequences, eventually delivered as a pool of molecules. The commercially available microchip-based synthesizers are based on the principle of phosphoramidite chemistry with slight modifications. The major differences between various microchip-based methods are the different mechanisms applied in deprotection and base coupling steps. There is light control, electrochemical, and inkjet printing methods.
Today, many companies synthesize oligonucleotides en masse for academic and commercial use. Microchip engineers can manufacture microscopic circuits into a microchip by controlling the silicon lattice’s chemical properties, making computer components increasingly tiny. Accordingly, manufacturers can manufacture microscopic reaction clusters on a silicon plate to decrease the volume while massively increasing the throughput of the synthesis process. By combining the phosphoramidite reaction with writing onto a silicon platform, manufacturers have fine control over where our DNA strands are synthesized, and the sequence of nucleotides they contain, and the phosphoramidite reactions can be massively scaled up without compromising quality. The Oligonucleotide pool library has various applications in genetics research, drug discovery, and diagnostics.
Market Overview:
The latest research study on the global Oligonucleotide Pool Library market finds that the global Oligonucleotide Pool Library market reached a value of USD 106.05 million in 2023. It’s expected that the market will achieve USD 266.17 million by 2029, exhibiting a CAGR of 16.58% during the forecast period.
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
October 17, 2023
Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE: DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. The milestone marks a significant achievement in the company’s 35-year-history—its entrance into the therapeutics space—and enables IDT to manufacture products for research use through to current good manufacturing practice (cGMP) grade cell and gene therapy reagents to provide researchers with a single partner that can help them rapidly transition from the lab to therapeutic development.
The 41,000-square-foot-site will produce cGMP cell and gene therapy reagents, including single guide RNAs (sgRNAs) and donor oligos for homology-directed repair (HDR) with additional offerings to follow. These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
Advantages of oligonucleotide libraries
The advantages of oligonucleotide libraries include economy, high throughput, low mutation rate, and short TAT. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs have the advantages of high therapeutic efficiency, low drug toxicity, and strong specificity. They currently have great potential in the treatment of metabolic diseases, genetic diseases, cancer, and prevention of infectious diseases. It is expected to become the third largest category of drugs after small molecule drugs and antibody drugs. Oligonucleotides are basic tools for regulating gene expression in biomedical and life science research and have been developed as gene-targeted therapeutic drugs. Applications include the treatment of viruses, tumors, and genetic diseases, molecular diagnosis, precision medicine, and gene sequencing. Oligos are considered one of the most important tools in present day molecular biology.
To still leverage oligo pools for library creation – despite their low yield, their short length, and high synthesis errors – several powerful techniques have been developed over the last years. These techniques managed to use oligo pools for creating DMS libraries, insertion libraries, or for direct in‐lab assembly of gene fragments, full genes, and pathways and, as such, have and will make many next‐generation protein sciences approaches economically feasible for many laboratories. While currently, most approved nucleic acid treatments are designed to treat rare diseases, the delivery technologies for these types of therapies are now being used to generate more broadly applicable genetic medications and have also allowed rapid vaccine development in pandemic situations. Furthermore, these platforms help the clinical translation of innovative techniques like gene-editing medicines. In the future with continuous breakthroughs in chemical modification and delivery technology, the bottleneck problem of oligonucleotide industrialization has gradually been solved, and the industry has entered a period of rapid development.
The growing prevalence of genetic diseases
Genetic disorders include both single-gene disorders, such as cystic fibrosis and sickle cell disease, and conditions that make people more likely to develop common chronic diseases, such as hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia. There are an estimated 10,000 different types of monogenic diseases, which are caused by mutations in a single gene. The World Health Organization estimates that 10 out of every 1,000 people are affected. This means that 70 million to 80 million people in the world suffer from one of these diseases. Due to the continuous improvement and advancement of technology over the past 30 years, gene therapy has become a potential treatment option for more patients with genetic diseases. Synthetic oligonucleotides are shown to be efficient laboratory tools to regulate the expression of specific genes. Antisense oligonucleotides (ASOs) are short oligonucleotides that can modify gene expression and mRNA splicing in the nervous system. The FDA has approved ASOs for the treatment of ten genetic disorders, with many applications currently in the pipeline. Various initiatives taken by governments to promote genetic testing and high investments in healthcare infrastructure with a focus on strengthening the diagnostics sector are also having a positive impact on the market. For example, the U.S. government supports newborn screening tests to reduce cases of genetic disorders through early detection, diagnosis, and intervention in the country's newborns. Governments are investing in strengthening healthcare infrastructure to provide better medical facilities and enhance genomic innovation and technological advancements.
Region Overview:
In 2022, the share of the Oligonucleotide Pool Library market in North America stood at 41.32%.
Company Overview:
The major players operating in the Oligonucleotide Pool Library market include Agilent, Integrated DNA Technologies, Twist Bioscience, CustomArray, Creative Biogene, etc. Among which, Agilent ranked top in terms of sales and revenue in 2023.
Agilent supports scientists in 110 countries in cutting-edge life science research; patient diagnostics; and testing required to ensure the safety of water, food and pharmaceuticals. Agilent's advanced instruments, software, consumables, and services enable customers to produce the most accurate and reliable results as well as optimal scientific, economic, and operational outcomes.
Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Agilent teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories.
Segmentation Overview:
By type, DNA Oligos segment accounted for the largest share of market in 2022.
Application Overview:
By application, the CRISPR/Cas9 Designs segment occupied the biggest share from 2018 to 2022.
Key Companies in the global Oligonucleotide Pool Library market covered in Chapter 3:
Creative Biogene
Dynegene Technologies
CustomArray
Daicel Arbor Biosciences
General Biosystems
LC Sciences
Agilent
Integrated DNA Technologies
Synbio Technologies
Twist Bioscience
In Chapter 4 and Chapter 14.2, on the basis of types, the Oligonucleotide Pool Library market from 2019 to 2030 is primarily split into:
DNA Oligos
RNA Oligos
In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Oligonucleotide Pool Library market from 2019 to 2030 covers:
Target Capture
CRISPR/Cas9 Designs
Gene Synthesis
Library Preparation
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:
North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)
Column-based oligo synthesis is the first-generation technology based on phosphoramidite chemistry. Column-based oligonucleotide synthesis cannot satisfy the requirements of large-scale DNA synthesis in the era of synthetic biology, due to the limitations of low throughput and high cost. In the 1990s, oligo synthesis gradually developed into a higher throughput manner by parallel synthesis on a silica surface. This microchip-based (also called ‘microarray-based’) large-scale oligo synthesis technology, surpassing the column-based synthesis in terms of throughput and cost, has received wide attention.
A promising route is to harness existing DNA microchips, which can produce up to a million different oligonucleotides on a single chip, as a source of DNA. Recently, the quality of microchip-synthesized oligonucleotides was improved by controlling depurination during the synthesis process. These arrays produce up to 55,000 200-mer oligonucleotides on a single chip and are sold as a ~1–10 picomole pools of oligonucleotides, termed OLS pools (oligo library synthesis). The currently cheapest available source of synthetic DNA is micro‐array‐synthesized oligonucleotides, commercially available as oligo pools. Oligo pools are mixes of thousands of individually designed polynucleotides of up to 350 bases in length. Microarray‐based technologies allow the synthesizing of thousands of individual user‐defined sequences, eventually delivered as a pool of molecules. The commercially available microchip-based synthesizers are based on the principle of phosphoramidite chemistry with slight modifications. The major differences between various microchip-based methods are the different mechanisms applied in deprotection and base coupling steps. There is light control, electrochemical, and inkjet printing methods.
Today, many companies synthesize oligonucleotides en masse for academic and commercial use. Microchip engineers can manufacture microscopic circuits into a microchip by controlling the silicon lattice’s chemical properties, making computer components increasingly tiny. Accordingly, manufacturers can manufacture microscopic reaction clusters on a silicon plate to decrease the volume while massively increasing the throughput of the synthesis process. By combining the phosphoramidite reaction with writing onto a silicon platform, manufacturers have fine control over where our DNA strands are synthesized, and the sequence of nucleotides they contain, and the phosphoramidite reactions can be massively scaled up without compromising quality. The Oligonucleotide pool library has various applications in genetics research, drug discovery, and diagnostics.
Market Overview:
The latest research study on the global Oligonucleotide Pool Library market finds that the global Oligonucleotide Pool Library market reached a value of USD 106.05 million in 2023. It’s expected that the market will achieve USD 266.17 million by 2029, exhibiting a CAGR of 16.58% during the forecast period.
Integrated DNA Technologies Opens New Therapeutic Manufacturing Facility to Support Growing Demand in Genomic Medicine
October 17, 2023
Global genomics solutions provider Integrated DNA Technologies (IDT), an operating company in the Life Sciences segment of Danaher Corporation (NYSE: DHR), today announced the completion of its new Therapeutic Oligonucleotide Manufacturing facility in Coralville, Iowa. The milestone marks a significant achievement in the company’s 35-year-history—its entrance into the therapeutics space—and enables IDT to manufacture products for research use through to current good manufacturing practice (cGMP) grade cell and gene therapy reagents to provide researchers with a single partner that can help them rapidly transition from the lab to therapeutic development.
The 41,000-square-foot-site will produce cGMP cell and gene therapy reagents, including single guide RNAs (sgRNAs) and donor oligos for homology-directed repair (HDR) with additional offerings to follow. These new capabilities and offerings will be supported with comprehensive documentation and testing, a support team, and regulatory guidance to help accelerate researchers’ path to the clinic.
Advantages of oligonucleotide libraries
The advantages of oligonucleotide libraries include economy, high throughput, low mutation rate, and short TAT. Compared with traditional small molecule drugs and antibody drugs, nucleic acid drugs have the advantages of high therapeutic efficiency, low drug toxicity, and strong specificity. They currently have great potential in the treatment of metabolic diseases, genetic diseases, cancer, and prevention of infectious diseases. It is expected to become the third largest category of drugs after small molecule drugs and antibody drugs. Oligonucleotides are basic tools for regulating gene expression in biomedical and life science research and have been developed as gene-targeted therapeutic drugs. Applications include the treatment of viruses, tumors, and genetic diseases, molecular diagnosis, precision medicine, and gene sequencing. Oligos are considered one of the most important tools in present day molecular biology.
To still leverage oligo pools for library creation – despite their low yield, their short length, and high synthesis errors – several powerful techniques have been developed over the last years. These techniques managed to use oligo pools for creating DMS libraries, insertion libraries, or for direct in‐lab assembly of gene fragments, full genes, and pathways and, as such, have and will make many next‐generation protein sciences approaches economically feasible for many laboratories. While currently, most approved nucleic acid treatments are designed to treat rare diseases, the delivery technologies for these types of therapies are now being used to generate more broadly applicable genetic medications and have also allowed rapid vaccine development in pandemic situations. Furthermore, these platforms help the clinical translation of innovative techniques like gene-editing medicines. In the future with continuous breakthroughs in chemical modification and delivery technology, the bottleneck problem of oligonucleotide industrialization has gradually been solved, and the industry has entered a period of rapid development.
The growing prevalence of genetic diseases
Genetic disorders include both single-gene disorders, such as cystic fibrosis and sickle cell disease, and conditions that make people more likely to develop common chronic diseases, such as hereditary breast and ovarian cancer syndrome, Lynch syndrome, and familial hypercholesterolemia. There are an estimated 10,000 different types of monogenic diseases, which are caused by mutations in a single gene. The World Health Organization estimates that 10 out of every 1,000 people are affected. This means that 70 million to 80 million people in the world suffer from one of these diseases. Due to the continuous improvement and advancement of technology over the past 30 years, gene therapy has become a potential treatment option for more patients with genetic diseases. Synthetic oligonucleotides are shown to be efficient laboratory tools to regulate the expression of specific genes. Antisense oligonucleotides (ASOs) are short oligonucleotides that can modify gene expression and mRNA splicing in the nervous system. The FDA has approved ASOs for the treatment of ten genetic disorders, with many applications currently in the pipeline. Various initiatives taken by governments to promote genetic testing and high investments in healthcare infrastructure with a focus on strengthening the diagnostics sector are also having a positive impact on the market. For example, the U.S. government supports newborn screening tests to reduce cases of genetic disorders through early detection, diagnosis, and intervention in the country's newborns. Governments are investing in strengthening healthcare infrastructure to provide better medical facilities and enhance genomic innovation and technological advancements.
Region Overview:
In 2022, the share of the Oligonucleotide Pool Library market in North America stood at 41.32%.
Company Overview:
The major players operating in the Oligonucleotide Pool Library market include Agilent, Integrated DNA Technologies, Twist Bioscience, CustomArray, Creative Biogene, etc. Among which, Agilent ranked top in terms of sales and revenue in 2023.
Agilent supports scientists in 110 countries in cutting-edge life science research; patient diagnostics; and testing required to ensure the safety of water, food and pharmaceuticals. Agilent's advanced instruments, software, consumables, and services enable customers to produce the most accurate and reliable results as well as optimal scientific, economic, and operational outcomes.
Around the world, Agilent’s people bring innovations, technologies, and services to the forefront of science. Agilent teams design and manufacture a wide array of advanced analytical, research, and diagnostic solutions and tools for use inside and outside laboratories.
Segmentation Overview:
By type, DNA Oligos segment accounted for the largest share of market in 2022.
Application Overview:
By application, the CRISPR/Cas9 Designs segment occupied the biggest share from 2018 to 2022.
Key Companies in the global Oligonucleotide Pool Library market covered in Chapter 3:
Creative Biogene
Dynegene Technologies
CustomArray
Daicel Arbor Biosciences
General Biosystems
LC Sciences
Agilent
Integrated DNA Technologies
Synbio Technologies
Twist Bioscience
In Chapter 4 and Chapter 14.2, on the basis of types, the Oligonucleotide Pool Library market from 2019 to 2030 is primarily split into:
DNA Oligos
RNA Oligos
In Chapter 5 and Chapter 14.3, on the basis of Downstream Industry, the Oligonucleotide Pool Library market from 2019 to 2030 covers:
Target Capture
CRISPR/Cas9 Designs
Gene Synthesis
Library Preparation
Others
Geographically, the detailed analysis of consumption, revenue, market share and growth rate, historic and forecast (2019-2030) of the following regions are covered in Chapter 8 to Chapter 14:
North America (United States, Canada)
Europe (Germany, UK, France, Italy, Spain, Russia, Netherlands, Turkey, Switzerland, Sweden)
Asia Pacific (China, Japan, South Korea, Australia, India, Indonesia, Philippines, Malaysia)
Latin America (Brazil, Mexico, Argentina)
Middle East & Africa (Saudi Arabia, UAE, Egypt, South Africa)
- Chapter 1 Market Definition and Statistical Scope
- Chapter 2 Research Findings and Conclusion
- Chapter 3 Key Companies’ Profile
- Chapter 4 Global Oligonucleotide Pool Library Market Segmented by Type
- Chapter 5 Global Oligonucleotide Pool Library Market Segmented by Downstream Industry
- Chapter 6 Oligonucleotide Pool Library Industry Chain Analysis
- Chapter 7 The Development and Dynamics of Oligonucleotide Pool Library Market
- Chapter 8 Global Oligonucleotide Pool Library Market Segmented by Geography
- Chapter 9 North America
- Chapter 10 Europe
- Chapter 11 Asia Pacific
- Chapter 12 Latin America
- Chapter 13 Middle East & Africa
- Chapter 14 Global Oligonucleotide Pool Library Market Forecast by Geography, Type, and Downstream Industry 2024-2030
- Chapter 15 Appendix
Research Assistance
Download our eBook: How to Succeed Using Market Research
Learn how to effectively navigate the market research process to help guide your organization on the journey to success.
Download eBook